drugset
drugset / Trial / NCT02143973

Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus

NCT02143973 ↗

Phase 2/3 Completed 167 enrolled Trevi Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 24 weeks.

Timeline

Start
2014-09
Primary completion
2016-01
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Nalbuphine Small molecule 120 mg —

Indications

No indication recorded.